Researchers at Ohio State University Comprehensive Cancer Center have identified the enzyme PGM3 as a key driver of glioblastoma, a deadly brain cancer. Blocking PGM3 disrupts sugar-fat interactions crucial for tumour growth. Published in Science Advances, the study offers a promising new target for therapy and brings hope in the fight against treatment-resistant glioblastoma.